Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Tetraphase (NASDAQ:TTPH) and La Jolla Pharma (NASDAQ:LJPC).
Tetraphase (TTPH)
Needham analyst Alan Carr maintained a Hold rating on Tetraphase today. The company’s shares opened today at $2.92, close to its 52-week low of $2.05.
Carr commented:
“Tetraphase reported 2Q18 financial results yesterday and we spoke with mgmt for a corporate update. As a reminder, the EMA CHMP issued a positive opinion for Xerava last week. Approval in Europe is likely in Sept or Oct 2018. Xerava is also under review by the FDA, w/ an 8/27/18 PDFUA date. We expect approval. Mgmt has guided for launch in the U.S. in early 4Q18 and in UK and Germany in early 2019. Maintain HOLD, given our concerns over peak sales potential. Although Xerava is an effective antibiotic, we believe the commercial opportunity for new antibiotics in the IV Gram-negative hospital market may be modest.”
According to TipRanks.com, Carr is a 3-star analyst with an average return of 3.6% and a 41.6% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Rhythm Pharmaceuticals Inc, and Lexicon Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tetraphase with a $6 average price target.
See today’s analyst top recommended stocks >>
La Jolla Pharma (LJPC)
In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on La Jolla Pharma, with a price target of $115. The company’s shares opened today at $33.72.
Amusa noted:
“We further note CMS has a view consistent with our LJPC bull thesis, namely “that GIAPREZA™ represents a substantial clinical improvement over existing technologies because it quickly and effectively raises MAP while allowing for a reduction in other vasopressors”. We previously in our 27 February 2018 research noted, “…low market awareness of the NTAP process which could play out by 2H18, thereby supporting Giapreza uptake”.”
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 26.0% and a 54.6% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Applied Genetic Technologies.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for La Jolla Pharma with a $59.60 average price target, a 76.7% upside from current levels. In a report issued on July 27, H.C. Wainwright also maintained a Buy rating on the stock with a $53 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
